|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
One of the hallmarks of Alzheimer's disease is the formation of neurofibrillary tangles, intracellular aggregates of hyperphosphorylated, mislocalized tau protein, which are associated with neuronal loss.
|
25374103 |
2015 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We observed SNPs within the HLA, MAPT and APOE regions jointly contributing to increased risk for FTD and AD or PD.
|
27899424 |
2017 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have investigated the relationship between hippocampal ischemia and Alzheimer's disease by means of a transient 10-min global brain ischemia in rats and determining the effect on Alzheimer's disease tau protein gene expression during 2, 7 and 30 days post injury.
|
30096486 |
2018 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, we show that the active production of small amounts of abnormal tau protein facilitates dysfunction and accumulation of otherwise normal tau, a significant implication for the pathogenesis of patients with Alzheimer's disease.
|
19074615 |
2009 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tauopathies are neurodegenerative disorders characterized by abnormal intracellular aggregates of tau protein, and include Alzheimer's disease, corticobasal degeneration, frontotemporal dementia, and traumatic brain injury.
|
27997993 |
2017 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The majority of filaments resembled the half-twisted ribbons described previously in cases of FTDP-17, with a minority of filaments resembling the paired helical filaments of Alzheimer's disease.
|
12417659 |
2002 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, none of these factors induces AD independently, but they are all associated with the formation of Aβ and tau proteins.
|
29112116 |
2017 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therapeutic strategies focusing on the reduction of oxidative stress, modulation of amyloid-beta (Aβ) toxicity and inhibition of tau protein hyperphosphorylation are warranted to avoid the development and progression of AD.
|
30763379 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this review, we give a brief description of the pathogenesis of AD and provide detailed discussions about the recent development of chemical structures of anti-AD agents (2013 up to present) that have multiple targets, such as amyloid-β peptide, Tau protein, cholinesterases, monoamine oxidase, β-site amyloid-precursor protein-cleaving enzyme 1, free radicals, metal ions (Fe2+, Cu2+, Zn2+) and so on.
|
30501591 |
2019 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Presenilins have been associated with FTD or with FTD-like phenotype, while mutations in the MAPT gene have been linked to a clinical phenotype of AD.
|
19768372 |
2010 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The results presented here indicate that seladin-1 transcription is selectively down-regulated in brain regions vulnerable to Alzheimer's disease and this down-regulation is associated with the hyperphosphorylation of tau protein.
|
12127087 |
2002 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The present work was to explore whether BBR ameliorates cognitive deficits in AD and to investigate whether its underlying mechanism involves inhibiting hyperphosphorylated tau protein.
|
29132092 |
2017 |
|
Alzheimer's Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we found that streptozotocin (STZ)-induced diabetic rats exhibited poorer performance on the social recognition test, Morris water maze, and plus-maze discriminative avoidance task, compared to PBS-treated normoglycemic control rats, likely resulting from increased brain deposition of amyloid-β peptide aggregates (Aβ) and increased phosphorylation of tau protein, two pathological features of AD.
|
30958383 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genetic studies in Drosophila have revealed some key aspects of the normal function of Appl and Tau, the fly homologues of AβPP and MAPT that may be disrupted during AD.
|
25697708 |
2015 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is the most common neurodegenerative disorder which is characterized by the deposits of intra-cellular tau protein and extra-cellular amyloid-β (Aβ) peptides in the human brain.
|
29634991 |
2018 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The transition between soluble intrinsically disordered tau protein and aggregated tau in neurofibrillary tangles in Alzheimer's disease is unknown.
|
29472250 |
2018 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have generated transgenic mice expressing the shortest human tau protein, the microtubule-associated protein that composes paired helical filaments in Alzheimer's disease.
|
9916940 |
1999 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.
|
23585566 |
2013 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease is characterized in part by the intracellular misfolding and aggregation of tau protein.
|
27975246 |
2017 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Compared to older Caucasians, older African Americans have higher risks of developing Alzheimer disease (AD) and lower cerebrospinal fluid (CSF) tau biomarker levels.
|
31271450 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recent evidence has suggested that an abnormal reactivation of the cell cycle may precede and cause the hyperphosphorylation and filament formation of tau protein in Alzheimer's disease and other tauopathies.
|
16507903 |
2006 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Biochemical modifications of tau proteins have been proposed to be among the earliest neurobiological changes in Alzheimer's disease (AD) and correlate better with cognitive symptoms than do beta-amyloid plaques.
|
18511295 |
2008 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Deposits of abnormally hyperphosphorylated tau are a hallmark of several dementias, including Alzheimer disease (AD), and about 10% of familial frontotemporal dementia (FTD) cases are caused by mutations in the tau gene.
|
18852354 |
2008 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Assembly in vitro of tau protein and its implications in Alzheimer's disease.
|
15975073 |
2004 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The accumulation of beta-amyloid (A beta) plaques and neurofibrillary tangles consisting of hyperphosphorylated tau protein are pathological features of Alzheimer's disease (AD) commonly modeled in mice using known human familial mutations; however, the loss of neurons also found to occur in AD is rarely observed in such models.
|
18974993 |
2008 |